FDA to Explore Importing Certain Drugs When Access Threatened

Jul 19, 2018 - 03:20 PM
FDA-update-generic-drugs

The Food and Drug Administration is forming a work group to explore whether and how to temporarily import suitable substitutes for critical drugs with only one manufacturer, and no patents or exclusivities, when price increases or supply disruptions create significant barriers to patient access, FDA Commissioner Scott Gottlieb, M.D., announced today. The work group will examine issues such as the statutory and regulatory requirements relevant to developing and advancing such a policy. In other news, the FDA yesterday released a plan to speed biosimilar products to market and final guidance on labeling for biosimilar products. The plan focuses on streamlining and clarifying the product development and approval process; educating clinicians, patients and payers about biosimilars; and reducing anticompetitive behavior. While FDA has approved 11 biosimilars, only three are currently marketed in the U.S. According to a study the agency plans to release soon, Americans would have saved more than $4.5 billion in 2017 if all approved biosimilars were on the market, Gottlieb said.

Related News Articles

Headline
DEA, HHS extend telemedicine waivers through 2026
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
CMS proposes new drug pricing model to expand GLP-1 access to those with Medicare Part D and Medicaid
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
CMS releases proposed rules on two drug pricing models
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
Administration reaches deals with 9 drug companies to lower drug costs
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
Blog: Putting 340B Program Growth in Context
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
U.S. reaches trade agreement with U.K. on drug pricing
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…